Welcome to our dedicated page for Arcadia Biosciences news (Ticker: RKDA), a resource for investors and traders seeking the latest updates and insights on Arcadia Biosciences stock.
Arcadia Biosciences, Inc. (NASDAQ: RKDA) is a pioneering company in the field of agricultural biotechnology, focused on developing and marketing high-value food ingredients and nutritional oils. The company’s mission is to meet the growing consumer demand for healthier dietary options through its innovative product offerings.
Among Arcadia’s standout products are its GoodWheat™ branded ingredients, which provide significant health benefits and allow consumer packaged goods companies to differentiate their brands in a competitive marketplace. Additionally, Arcadia is committed to enhancing agricultural productivity and sustainability through its portfolio of agricultural traits. These traits are designed to help farmers around the world increase crop yields and reduce the environmental impact of farming practices.
The company is engaged in science-based approaches to crop improvement, with a focus on wheat, soy, and hemp. These efforts aim not only to improve the performance of these crops in the field but also to enhance their value in food, health, and wellness products, as well as their industrial applications.
Arcadia’s consumer brands cater to a range of markets, including food, beverage, and body care. Some notable brands include GoodWheat™ high-fiber pasta and Zola coconut water. These products highlight the company’s dedication to providing nutritious and beneficial options to consumers.
Recent achievements and ongoing projects reflect Arcadia’s commitment to innovation and sustainability. By leveraging advanced agricultural biotechnology, the company continues to contribute to a healthier future while supporting global agricultural productivity.
For more detailed information and the latest updates, visit their official website at www.arcadiabio.com.
Arcadia Biosciences, Inc. (Nasdaq: RKDA) will release its Q1 2022 financial results on May 12, 2022, after market close. A conference call to discuss the results is scheduled for 4:30 p.m. Eastern time on the same day, with dial-in numbers provided. The company specializes in plant-based health products and has a range of offerings including GoodWheat™ and Zola® coconut water. A live webcast of the call will be available on Arcadia's investor website, with a recorded replay following the event.
Arcadia Biosciences (Nasdaq: RKDA) announced its fourth quarter and full-year 2021 financial results, revealing a significant revenue decline of 70% in Q4 2021 to $2.2 million, compared to $7.1 million in Q4 2020. Annual revenue also fell by 16% to $6.78 million. Operating expenses surged to $15.975 million in Q4 and $42.306 million for the year, leading to a net loss of $9.282 million for Q4 and $14.660 million for 2021. The company focuses on expanding its GoodWheat portfolio and recently appointed CPG industry veteran Stan Jacot as CEO to enhance growth strategies.
Arcadia Biosciences, Inc. (Nasdaq: RKDA) announced it will release its 2021 fourth-quarter and full-year financial results after market close on March 30, 2022. A conference call is scheduled for 4:30 p.m. Eastern time to discuss the results and the company’s key strategic achievements over the year. Participants can join via U.S. Toll-Free Dial-In: +1-844-243-4690 or International Dial-In: +1-225-283-0138. A live webcast will be available on the company’s investor section, with a replay to follow.
Arcadia Biosciences (RKDA) has appointed Stan Jacot as the new CEO, effective February 2, 2022. Jacot brings a wealth of experience from his previous roles, including a successful tenure at Jane's Dough Foods, where he achieved significant growth. He aims to leverage Arcadia's innovative, plant-based product portfolio, highlighting the upcoming launch of GoodWheat pasta. The board's decision follows a nationwide search, and Jacot's appointment includes a stock option grant of 316,108 shares at an exercise price of $0.91, vesting over four years.
Arcadia Biosciences, Inc. (Nasdaq: RKDA) appointed Kevin Comcowich as interim CEO effective January 1, 2022, while the board finalizes its search for a permanent replacement. Comcowich, the current Chairman since 2017, takes over following the departure of Matthew Plavan, the CEO since 2019, on December 31, 2021. The company is expanding into the consumer packaged goods sector, emphasizing plant-based health products.
Arcadia Biosciences (Nasdaq: RKDA) has appointed Brian Schaffer as Senior Vice President of Sales to spearhead the retail launch of its GoodWheat brand in 2022. Schaffer brings extensive experience from top CPG firms like PepsiCo and Kellogg's, enhancing the company's strategy in a competitive market. His predecessor, Chris Cuvelier, will leave the company on November 30 to pursue other opportunities. This leadership change aims to bolster growth in Arcadia's plant-based health products, including Zola coconut water and Saavy Naturals.
Arcadia Biosciences, Inc. (Nasdaq: RKDA) reported significant growth in Q3 2021 with revenues soaring to $2.4 million, a 657% increase from $314,000 in Q3 2020. The nine-month revenue grew to $4.6 million, a 410% rise from the previous year. This growth was attributed to the newly acquired wellness brands and increased sales of GoodHemp and GoodWheat products. However, total operating expenses also rose to $11.1 million, leading to a net loss of $2.2 million, down from $6.4 million a year earlier. The company is set for a full launch of its GoodWheat pasta line in Q1 2022.
Arcadia Biosciences (Nasdaq: RKDA) will disclose its Q3 financial results and business highlights on November 15, 2021. The announcement follows their strategy to enhance plant-based health products. A conference call is scheduled for 4:30 p.m. Eastern time to review the outcomes and significant achievements. Investors can join via U.S. Toll-Free or International Dial-In numbers. A live webcast will also be available on their investor website, along with a replay post-call.
Arcadia Biosciences (Nasdaq: RKDA) has announced a national search for a new CEO as Matt Plavan prepares to step down, likely by year-end. Plavan, who joined in 2016 and became CEO in 2019, has led the company through a pivotal transformation from agricultural biotech to consumer packaged goods (CPG). The board emphasizes the need for a leader with CPG experience to build on the current momentum and capitalize on growth opportunities. Arcadia's product portfolio includes health and wellness brands such as GoodWheat and Lief.
Arcadia Biosciences (Nasdaq: RKDA) reported five-fold revenue growth for Q2 2021, reaching $1.4 million compared to $281,000 in Q2 2020. Total revenues for the first half of 2021 were $2.2 million, up from $590,000 a year earlier. The net loss attributable to common stockholders improved 46% to $5.3 million. Key developments include the integration of operations post-Lief acquisition and the sale of Bioceres shares for over $27 million. The appointment of experienced CPG leaders aims to enhance brand awareness and growth.
FAQ
What is the current stock price of Arcadia Biosciences (RKDA)?
What is the market cap of Arcadia Biosciences (RKDA)?
What does Arcadia Biosciences, Inc. specialize in?
What are some of Arcadia’s notable product brands?
How does Arcadia Biosciences contribute to agricultural sustainability?
What crops does Arcadia Biosciences focus on?
How does Arcadia Biosciences enhance the value of crops?
Where can I find more information about Arcadia Biosciences?
What recent achievements has Arcadia Biosciences made?
How does Arcadia Biosciences help consumer packaged goods companies?
What is the mission of Arcadia Biosciences?
What sectors does Arcadia Biosciences operate in?
